Peptech Biosciences has received the approval for the grant of registration for Technical Indigenous Manufacture of Paclobutrazol technical 95% w/w min. u/s 9(4) from the Central Insecticide Board and Registration Committee (CIBRC). The company has received the final approval from the registration committee in 434th RC meeting held recently.
“We are very glad to receive the approval of Paclobutrazol Technical from CIBRC. Apart from conventional molecules, the company has been robustly working on innovative products that ensure good profitability to the farmers,” said Suresh Chand Singla, Managing Director, Peptech Biosciences. Today, Peptech Biosciences has a bigger portfolio ranging from crop protection to crop and soil nutrition and crop enhancers. The company adds that its strong R&D team is working dedicatedly to deliver state-of-the-art product solutions. Peptech already holds licenses for more than 150 molecules under the CIBRC and assures that there are more under the registration process. Even the company holds registration under FCO for various fertilisers and bio-stimulants.
You may also like to read: UPL raises second tranche of USD700 million sustainability linked loan
A triazolic plant growth regulator, the main role of Paclobutrazol is to maintain the health and vitality of plants and promote compactness. The mode of action is defined by blocking gibberellin biosynthesis and reducing abscisic acid, ethylene and indole-3-acetic acid (IAA) levels along with increasing cytokinin levels. It has been predicted that at a compound annual growth rate (CAGR) of 5.2 per cent, the global market for Paclobutrazol is growing. The growth will get a boost when there is a notable increase in awareness towards food security and a decline in the utilisation of arable land. It is believed that the demand for this effective plant growth regulator would increase by 2025.